Natural products have always been important resources either as therapeutic agents or as lead compounds for the production of pharmaceutical compounds. Osthole, 7-methoxy-8-(3-methyl-2-butenyl) coumarin, an ingredient of a Traditional Chinese Medicine(TCM), has received considerable attention recently because of its significant and diverse pharmacological activities, including anticancer, antisteoporotic, and antiproliferative, which make it a very promising natural lead compound for new drug discovery. The present work summarizes the related biological information on osthole and its analogues and proposes the possibility of its development as a promising lead compound for drug discovery.
Natural products and their derivatives have historically been invaluable as a resource of therapeutic agents. Currently, a large number of compounds derived from natural product sources have been approved for clinical trials and the market [1, 2] . However, in the past decades, research into natural products in the pharmaceutical industry has declined, owing to issues such as the lack of compatibility of traditional natural-product extract libraries with high-throughput screening [3] . Recent technological advances that help to address these issues, coupled with unrealized expectations from current lead-generation strategies, have led to a renewed interest in natural products in drug discovery [4] [5] [6] . It has long been recognized that naturalproduct structures have the characteristics of high chemical diversity, biochemical specificity and other properties that make them favorable as lead structures for drug discovery, and which also differentiate them from libraries of synthetic and combinatorial compounds. Various investigators have worked to measure by means of computational chemistry those desirable chemical features that distinguish natural products from other sources of drug leads [7, 8] . Osthole, 7-methoxy-8-(3-methyl-2-butenyl)coumarin, is a coumarin derivative clinically ingested as a component of medicinal plants and herbs [9, 10] ( Figure 1 ), and it exhibits many pharmacological and biological activities [11] [12] [13] . The original study of osthole dates back to 1909. It was first discovered from Peucedanum ostruthium. The content of osthole is higher than 1% in Cnidium monnieri (L) Cusson. Osthole has now been found to be distributed widely in the plant kingdom and also to be present in notable amounts in several species. It mainly occurs in 14 species of Umbelliferae and 17 of Rutaceae. It has also been found in some species of Leguminosae and Compositae. Cnidium monnier (L.) Cusson, which contains a high percentage of osthole, has been utilized in China for several hundred years as an herbal medicine to treat male sexual dysfunction and for other indications. Practically from the beginning of the study of osthole, the attention of the investigation was focused on the possibility of its therapeutic activity and it appears that the compound may have an important role to play in liver health, brain function, and vasodilation.
This review provides a summary of the current knowledge of osthole and analogues, especially focused on their biological properties, and proposes the possibility of their future development as promising lead compounds.
Biological activity of osthole and its analogues
According to the publications related to osthole and its analogues in the last 10 years, the pharmacological functions of these compounds have proved versatile, and these are summarized in this review. Up to the present, osthole has being selected for development as an hepatoprotectant [14] , as well as an antipruritic [15] . It is apparent that osthole has an important role to play in liver health, brain function and vasodilation, and also could lead to more comprehensive and wider applications as antihepatitis, anti-oxidation, anti-tumor, and cardiovascular agents, as well as for menopausal osteoporosis and immunity-strengthening. Therefore, osthole has good opportunities to be developed as a lead compound for various disease therapies based on further modification and optimization.
Anti-hepatitis activity:
Studies with hepatitis model mice revealed that osthole can prevent hepatitis by inhibiting the development of apoptosis [16, 17] , which indicated that osthole has some possibilities to become a hepatoprotective drug candidate for a wide variety of liver diseases [14] .
Osthole prevents anti-Fas antibody-induced hepatitis by inhibiting the Fas-mediated apoptotic pathway. Pretreatment of mice with osthole (10, 50 and 100 mg/kg, i.p.) prevented the elevation of plasma alanine aminotransferase (ALT) caused by anti-Fas antibody (175 mug/kg, i.v.). Administration of osthole to mice, even at a dose of 10 mg/kg, significantly inhibited anti-Fas antibody-induced elevation of plasma ALT. Capase-3 is a cysteine protease and the treatment of mice with anti-Fas antibody caused an elevation of caspase-3 activity at 3.5 and 6 hours. Pretreatment of mice with osthole (100mg/kg, i.p.) inhibited the elevation of caspase-3 activity caused by anti-Fas antibody. In comparison, the addition of osthole (up to 10μM) to a liver cytosol fraction isolated from mice which had been treated with anti-Fas antibody did not inhibit caspase-3 activity in vitro. Thus, treatment of mice with osthole inhibited caspase-3 activity by an effect upstream of caspase-3 activation. The livers of mice treated with anti-Fas antibody contained apoptotic and dead cells; osthole attenuated the development of this apoptosis and cell death [17] .
At the dose of 200 mg/kg (i.p.), osthole inhibited more than 90% of the Con A-induced elevation of plasma ALT activity. The inhibitory activity of osthole is lost when its 7-methoxy group is replaced by a 7-hydroxy group to form osthenol.
Osthole was also revealed to have the capability of inhibiting the secretion of hepatitis B virus (HBV) surface antigens in vitro. The secretion of hepatitis B surface antigen (HBsAg) in culture medium of RIS-GS and HuH-7 cells that was transfected with HBV DNA decreased by 60-70% after treatment with osthole; meanwhile, no detectable cytotoxic effects were observed. The inhibition produced by osthole probably resulted from its complex function in increasing the glycosylation of HBsAg. [16] Recently, several osthole derivatives (2-4, Figure 2 ) were described as showing stronger inhibition of Con A-induced elevation of ALT. Oral administration of osthole at a dose of 100 mg/kg inhibited 38.0 % of the concanavalin-A (Con-A)-induced elevation of plasma ALT. In contrast, oral administration of the most potent derivative, 2, at a dose of 100 mg/kg could reach 88.3% inhibition of the Con A-induced elevation of plasma ALT, respectively. These synthetic osthole derivatives could contribute to the development of effective hepatoprotective drugs [14] .
Alleviating hyperlipidemic fatty liver: Osthole was also reported to have therapeutic effects on both alcohol and fatty milk-induced rat fatty liver. Zhang reported [13] that after treatment with osthole, the levels of rat serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol significantly decreased in comparison with the fatty liver model group (P < 0.05 or P < 0.01). Hepatic weight and its coefficient, the hepatic tissue contents of TC, TG, and malondialdehyde, were also significantly decreased (P < 0.05 or P < 0.01). In fatty milk-induced hyperlipidemic mice, the post-heparin plasma activities of lipoprotein lipase (LPL), hepatic lipase (HL), and total lipase (TL) significantly increased after treatment with 10-20 mg/kg osthole for 3 weeks (P < 0.05 or P < 0.01). Importantly, the histological evaluation of rat liver demonstrated that osthole dramatically decreased lipid accumulation (P < 0.01). The mechanism might be associated with its anti-oxidation and elevation of LPL and HL activities.
Osthole also exhibited therapeutic effects on fat milkinduced fatty liver in rats, by regulating mRNA expression of the target genes of CYP7A, DGAT, L-FABP and FATP4 by increasing PPAR α/γ mRNA expression. In rats with alcohol-induced fatty liver, the level of malondialdehyde in liver was decreased.
Osthole was thus proved to have moderate therapeutic effects on alcohol-affected livers [13] .
Osteoporosis activity: Osthole demonstrates a significant induction of differentiation in two human osteoblast-like cell lines, human osteosarcoma cell line (MG-63) and human fetal osteoblastic cell line (hFOB). Induction of differentiation by osthole was associated with increased bone morphogenetic protein (BMP)-2 production and the activation of SMAD1/5/8 , p38 and extracellular signal-regulated kinase (ERK). Addition of purified BMP-2 protein did not increase the up-regulation of ALP activity and osteocalcin by osthole, whereas the BMP-2 antagonist noggin blocked both osthole and BMP-2mediated ALP activity enhancement, indicating that BMP-2 production is required in osthole-mediated osteoblast maturation. However, pretreatment of osteoblast cells with noggin abrogated p38 activation, and partially decreased ERK1/2 activation, suggesting that BMP-2 signaling is required in p38 activation, and is partially involved in ERK1/2 activation in osthole-treated osteoblast cells. Cotreatment with either p38 inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinyl-phenyl)-5-(4pyridyl)-1H-imidazole] or p38 small interfering RNA (siRNA) expression inhibited osthole-mediated activation of ALP, but only slightly affected osteocalcin production. In contrast, the production of osteocalcin induced by osthole was inhibited by the mitogen activated protein kinase inhibitor PD98059 (2'-amino-3'-methoxyflavone) or by expression of an ERK2 siRNA. These data suggest that the BMP-2/p38 pathway links to the early phase, whereas the ERK1/2 pathway is associated with the later phase in osthole-mediated differentiation of osteoblast cells. In this study, Kuo demonstrated that osthole is a promising agent for the treatment of osteoporosis [18] .
Osthole significantly promoted the activity of osteoblast-like UMR106 cells [19] . Fas (Apo-1/CD95) ligand, which is a type II membrane protein, is a major inducer of apoptosis. Pretreatment of mice with osthole (10, 50, and 100 mg/kg, i.p.) prevented the elevation of plasma ALT caused by anti-Fas antibody (175 mug/kg, i.v.). Administration of osthole to mice, even at a dose of 10 mg/kg, significantly inhibited anti-Fas antibody-induced elevation of plasma ALT. Caspase-3 is a cysteine protease. Treatment of mice with anti-Fas antibody caused an elevation of caspase-3 activity at 3.5 and 6 hr. Pretreatment of mice with osthole (100 mg/kg, i.p.) inhibited the elevation of caspase-3 activity caused by anti-Fas antibody. However, the addition of osthole to a liver cytosol fraction isolated from mice treated with anti-Fas antibody did not inhibit caspase-3 activity in vitro. Thus, treatment of mice with osthole inhibited caspase-3 activity by an effect upstream of caspase-3 activation. The livers of mice treated with anti-Fas antibody contained apoptotic and dead cells; osthole attenuated the development of this apoptosis and cell death. By inhibiting the Fasmediated apoptotic pathway, osthole prevented anti-Fas antibody-induced hepatitis Improvement of reproduction system: Osthole (3 and 10 mg/kg, s.c.) improved the performance deficit in ovariectomized (OVA) rats. It (10 and 30 mug/brain, icv) also improved the performance deficit caused by scopolamine (SCOP) in intact female rats, and at 30 mug/brain improved the deficit in OVA rats. The action mechanism of the effects of osthole on performance deficits was related to the estrogen-like properties and activation of the central cholinergic neuronal system [20] .
Corpus cavernosal strips showed relaxation in response to osthole (0.1 similar to 30 muM) in a dose-dependent manner. These effects were reduced partially, but significantly by pretreatment with L-NAME, ODQ and by endothelial disruption. However, they were not affected by indomethacin and tetradotoxin treatment. Osthole pretreatment (from 1 to 30 muM) enhanced the sodium nitroprusside (0.3 muM)-induced relaxation of corpus cavernosum in a dose-dependent manner to a maximum of 3 times the pretreatment level at 30 mu M osthole. However, this effect was abolished in the presence of zaprinast. Additionally, a higher concentration of osthole (30 muM) also enhanced forskolin-induced relaxation. The data suggested that osthole possesses a relaxant effect on rabbit corpus cavernosal tissues, which is attributable to the release of NO from sinusoidal endothelium and to the potentiation of the cGMP and/or cAMP signal mediating relaxation of cavernosal smooth muscle by inhibiting phosphodiesterase [21] .
The organ coefficient of testis, epididymis and seminal vesicle in the kidney-YANG deficiency model of mice has been reported to increase after treated with osthole (150 mg/kg), as well as body weight, and prolongation of the swimming time rose significantly [22] . The LD 50 value of osthole is 3.60 ± 0.40 g by the oral route. It can be concluded that osthole can improve the deficiency symptoms of kidney-YANG and castrated male mice.
Anticancer activity:
The in vitro studies with osthole showed that it inhibited the growth of HeLa, in a time-and concentration-dependent manner, with IC 50 values of 78.0 and 64.9 μM after 24 and 48 h, respectively. Osthole had lower cytotoxic effects in primary cultured normal cervical fibroblasts. The increased DNA fragmentation and activated PARP in HeLa after treatment with osthole could induce apoptosis. The results of the in vivo model showed that survival of the P-388 D1 tumor-bearing CDF1 mice was prolonged (ILS% = 37) after osthole (30 mg/kg) was administered once a day for 9 days. Based on these results, it was suggested that osthole could inhibit P-388 D1 cells in vivo and induce apoptosis in HeLa cells in vitro, and that osthole is a good lead compound for developing antitumor drugs [23] .
Another paper also described the antitumor activities of osthole both in vitro and in vivo. An in vitro antitumor assay was performed with human pulmonary A549 adenoma cells and Bel-7402 liver cancer cells. For the in vivo trial, mouse liver solid tumor H22 was selected and a conventional assay method was employed. Three different doses of osthole were administered orally, and tumor inhibitory percentage, thymus gland, spleen indexes and liver weight were measured. The IC 50 values for osthole in A549 and Bel-7402 cells were 67.8 μg/mL and 123.9 μg/mL, respectively. In vivo tumor inhibitory rates in H22 sarcoma were 62%-73%. All osthole-treated groups compared with control animals revealed a difference that was statistically significant (P < 0.01). However, the osthole-treated groups showed little differences in spleen index, thymus index, and liver weight compared with control mice (P>0.05). Nevertheless, when compared with the positive control drug cisplatin (5 mg/kg dosage), the thymus index, spleen index and liver weight were statistically different (P < 0.01). Overall, osthole had obvious antitumor activities both in vitro and in vivo, and did not reveal any toxic effects in experimental animals with the administered doses.
Beyond the above-mentioned functions, osthole was also reported to have many other activities, including antibacterial [24] , anticoagulant [10, 25] , and reduction of memory impairment induced by betaamyloid peptide [26, 27] .
Modification and optimization strategies
When considering the drug-like properties of osthole, it has a low MW and a high cLogp, but lacks a hydrogen-bond acceptor, as well as exhibiting low water solubility and bioavailability, which, most critically, might have to be improved in order to make the biological activity of the compound reach the requirements needed for a lead compound. A more polar group, like a hetero atom or a heterocyclic aryl ring could be considered for introduction to the structure to improve the bioactivity and physicochemical properties. Therefore, further modification or optimization has to be performed. On the other hand, osthole could be considered as a useful and universal fragment to combine with other pharmacophores, together targeting other special enzyme, protein and macromolecule acceptors for drug discovery.
Conclusion:
The natural product osthole exhibits comprehensive biological activity due to its unique structural features, which make it a good candidate for the generation of lead compounds. This review summarizes the latest progress with osthole and its analogues, and proposes the possibility of developing the lead compound into a potential drug. Since very limited modifications and optimizations have been performed on the osthole molecule, there are very good prospects for medicinal chemists to undertake more exploratory research.
